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The aim of this study was to determine the survivability of probiotics; Lactobacillus 
casei Shirota and Lactobacillus casei DN-114 001, within their respective 
commercialised food matrices Yakult and Actimel, during in vitro simulated 
gastrointestinal transit.  Original and Light/Fat Free varieties of each brand were 
assessed to determine whether nutritional composition affected bacterial survival 
rate.  Strains were exposed to 3 hours of simulated gastric transit at pH 2, using 
Hydrochloric Acid (32%) and Pepsin (3mg ml-1), followed by 2 hours of simulated 
duodenal transit, at pH 6.5, using Bile Salts (0.3% w/v) and Sodium Hydroxide (4M).  
Samples were serially diluted with PBS, spread plated onto MRS Agar and incubated 
at 37oC for 72 hours in a Carbon dioxide incubator (5%).  Strains within all products 
retained viability after 5 hours of simulated gastrointestinal transit.    Reductions in L. 
casei Shirota, within Yakult products (0.993 ± 0.220; Mean ± Standard Deviation), 
were significantly greater (P<0.05), after 5 hours of simulated gastrointestinal transit, 
than reductions in L. casei DN-114 001 within Actimel products (0.330 ± 0.129).  No 
significant correlation was observed between the variety of brand (Original or 
Light/Fat Free) and bacterial survival rate after 5 hours of simulated gastrointestinal 
transit.  Results suggest L. casei DN-114 001 is more capable at adapting to and 
surviving the inhospitable conditions of the gastrointestinal tract. However, food 
matrix composition may have some effect on bacterial survival as reductions of L. 
casei DN-114 001, within Actimel Fat Free (0.428 ± 0.059), after 5 hours of 
simulated gastrointestinal transit were proven significant (P<0.05), but were 
insignificant for L. casei DN-114 001 within Actimel Original, when compared to 
controls.  This study demonstrates that L. casei Shirota and L. casei DN-114 001, in 
Original and Light/Fat Free versions of Yakult and Actimel, have the potential to 
survive the upper gastrointestinal tract.   
 
Highlights 
 All strains retained viability after 5 hours of in vitro gastrointestinal transit 
 L. casei DN-114 001 in Actimel Original showed resistance to 
gastrointestinal transit 
 L. casei Shirota in Yakult products was significantly affected by 
gastrointestinal transit  
 Composition of food matrix is potentially correlated with bacterial survivability 
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Probiotics have been defined as “living microorganisms, which upon ingestion in 
certain numbers exert health benefits beyond inherent basic nutrition” (Guarner & 
Schaafsma, 1998).   The potential therapeutic use of bacteria was first proposed by 
Metschnikoff (1907) and it is now believed that bacterial probiotics exert health 
benefits by positively influencing the balance of microflora in the human 
gastrointestinal tract.  Lactic acid bacteria, primarily of the genus Lactobacillus, have 
been assessed extensively for their probiotic potential.  Certain Lactobacillus species 
have been shown to antagonise the growth of gastroenteric pathogens, such as 
Salmonella typhimurium, Helicobacter pylori and Pseudomonas aeruginosa (Bernet-
Camard et al, 1997; Sgouras et al, 2004). Furthermore, species of Lactobacillus 
reportedly enhance the efficacy of human gut-associated lymphoid tissue by 
augmenting non-specific and specific host immune responses (Gill, 1998).  Other 
proposed health benefits include the prevention of diarrhoeal diseases, anti-tumour 
action, cholesterol reduction, alleviation of allergic reactions and improvement of 
lactose utilisation (Kailasapathy & Chin, 2000).  Due to the vast range of potential 
therapeutic benefits, several Lactobacillus cultures have become commercialised as 
pharmaceuticals, nutritional supplements and functional foods; all of which have 
attached probiotic claims.  For example, fermented milk products, such as Yakult 
and Actimel, contain L. casei Shirota and L. casei DN-114 001 (also known as L. 
casei immunitas) respectively, both of which claim to support the indigenous 
microflora present in the human gut.  However, several remain sceptical of the 
probiotic functionality of commercialised products, primarily due to the physical and 
chemical barriers the bacterium has to overcome in order to exert their proposed 
benefits.  The bacterium has to remain viable and active during gastrointestinal 
transit, where the acidic conditions of the stomach and secretions of hydrolytic 
enzymes and bile in the small intestine decrease its chance of survival.  The 
bacterium must then defy the digestive flux of the human intestines and out-compete 
indigenous microflora to adhere to intestinal epithelia.  Several studies have 
assessed the ability of Lactobacillus species to resist in vitro simulated 
gastrointestinal tract conditions and adhere to intestinal epithelia.  Maragkoudakis et 
al (2006) examined 29 Lactobacillus strains of dairy origin for their ability to survive 
in vitro gastric conditions and to adhere to CaCO-2 cells.  Interestingly, it was 
demonstrated that L. casei Shirota and L. casei DN-114 001 retained no viability 
after 3 hours of exposure to pH 2 plus pepsin, or after 1 hour of exposure to pH 1.   
Contrarily, using an in vitro dynamic gastric model of digestion, Curto et al (2011) 
showed that L. casei Shirota and L. casei DN-114 001 both exhibited high tolerance 
to gastric and duodenal digestion and furthermore, both strains exhibited higher 
survival rates when milk matrices were used as opposed to water.  The major 
limitation of most studies, assessing gastrointestinal transit tolerance of 
commercialised probiotic bacteria, is that they are not assessed within the food 
matrix they are sold in and furthermore, the majority of studies assess resistance to 
gastric and duodenal transit separately; simulating in vivo digestion inadequately.  
 
The aim of this study was to determine the survivability of L. casei Shirota and L. 
casei DN-114 001, in their respective Yakult and Actimel commercial food 
matrices, during simulated in vitro gastric and subsequent duodenal digestion.  
Additionally, Original varieties and Light/Fat Free varieties of each probiotic brand 
were tested to determine if nutritional content affected the tolerance of each strain to 
simulated gastrointestinal conditions. 
 




Materials and Methods 
 
Biochemicals 
All biochemicals used were obtained from Sigma-Aldrich (Dorset, U.K). 
 
Determination of gastrointestinal transit tolerance 
An aliquot (10ml) of each probiotic culture (Yakult Original, Yakult Light, Actimel 
Original and Actimel Fat Free) was diluted with distilled water (1:10).  To simulate 
gastric digestion at pH 2, 100µl of Hydrochloric Acid (32%) and Porcine Gastric 
Mucosa Pepsin (final concentration of 3mg ml-1) were added at 0 hours.  Samples 
were placed in a shaking water bath for 3 hours at 200rpm to respectively simulate 
residence time in the stomach and peristalsis.  After 3 hours of simulated gastric 
digestion, 400µl of Sodium Hydroxide (4M), to increase the pH to 6.5, and Bovine 
Bile Salts (0.3% w/v) were added to simulate duodenal digestion.  Samples were 
incubated in the shaking water bath for a further 2 hours to simulate residence time 
in the duodenum.  Aliquots (1ml) were taken from each culture at 0, 3 and 5 hours 
immediately after any additions were made.  Samples were serially diluted ten-fold 
using PBS, spread plated onto MRS Agar and incubated at 37oC for 72 hours in a 
Carbon dioxide incubator (5%).  Controls were performed in the same way, but 
without the additions of Hydrochloric Acid, Pepsin, Sodium Hydroxide or Bile Salts.   
 
Statistical Analyses 
For each probiotic product, a Two-sample T-test was used to determine if reductions 
in bacterial counts, after 5 hours of exposure to simulated gastrointestinal transit, 
differed significantly from controls.  A General Linear Model was used to determine: 
1) if reductions in bacterial count, during simulated gastric, duodenal and total 
gastrointestinal transit, differed significantly between probiotic brands 
(Yakult/Actimel) and 2) if reductions in bacterial count, during simulated gastric, 
duodenal and total gastrointestinal transit, differed significantly between versions of 
probiotic brands (Original/Light).  A second General Linear Model was used to 
determine if bacterial count reductions of each strain after simulated gastric transit 




Overall effect of simulated gastrointestinal transit on bacterial viability 
Each strain, within all 4 probiotic products, retained viability after 5 hours of exposure 
to simulated gastrointestinal conditions, as shown in Figure 1.  Mean final counts 
ranged from 6.50 log10 CFU ml
-1, by L. casei Shirota in Yakult Light, to 8.36 log10 
CFU ml-1 by L. casei DN-114 001, in Actimel Fat Free. 
 
Results of a Two-sample T-test indicated that the overall reduction in bacterial count 
of L. casei Shirota, within Yakult Original (1.000 ± 0.157; Mean ± Standard 
Deviation), after 5 hours of simulated gastrointestinal transit, was significantly greater 
(T = 9.15; P<0.05) than the reduction in bacterial count observed in its control (0.078 
± 0.077).  Similarly, the overall reduction in bacterial count of L. casei Shirota within 
Yakult Light (0.986 ± 0.317), after 5 hours, was significantly greater (T = 5.35; 
P<0.05) than the reduction in bacterial count in its control (-0.006 ± 0.056).  The 
overall reduction in L. casei DN-114 001, within Actimel Fat Free (0.428 ± 0.059), 
was also significantly greater (T = -6.35; P<0.05) compared with its control (-0.035 ± 




0.112) but was notably lower than the overall reduction of L. casei Shirota in both 
Yakult Original and Yakult Light.   
 
 
Figure 1: Survival of L. casei Shirota and L. casei DN-114 001, within Yakult and Actimel 
products, during simulated gastrointestinal and control conditions. 
Values are means from three replicates ± Standard Error of the Mean.  Solid lines represent 
simulated gastrointestinal transit; 0-3 hours represents simulated gastric transit; 3-5 hours 
represents simulated duodenal transit.  Dotted lines represent controls. ●: L. casei DN-114 
001 within Actimel Original; X: L. casei DN-114 001 within Actimel Fat Free; : L. casei 
Shirota within Yakult Original; : L. casei Shirota within Yakult Light. 
 
L. casei DN-114 001 in Actimel Original was the only strain not to exhibit a 
reduction in overall bacterial count, after 5 hours, which was significantly greater 
than its control.  
  
Results of the first General Linear Model (shown in table 1) indicated that the 
reduction in bacterial count, after 5 hours of simulated gastrointestinal transit, was 
significantly different between brands (F = 38.41; P<0.05).  Using Tukey 
comparisons, L. casei Shirota within both versions of Yakult exhibited a significantly 
greater mean reduction in number (0.993 ± 0.220) compared with L. casei DN-114 
001 in versions of Actimel (0.330 ± 0.129). Whether the product was Original or of a 
Light/Fat Free variety, had no significant effect on the overall reduction in bacterial 
count.    After 5 hours of simulated gastrointestinal transit, L. casei Shirota within 
Yakult Original demonstrated the greatest reduction in number (1.000 ± 0.157), with 
L. casei DN-114 001, within Actimel Original, exhibiting the smallest bacterial count 
reduction (0.232 ± 0.095).  
 
Effect of simulated gastric transit on bacterial viability 
Results of the first General Linear Model (table 1) indicated that during simulated 

































by both brand (F = 33.91; P<0.05) and version of brand (F = 22.73; P<0.05).  L. 
casei Shirota within Yakult products exhibited, on average, significantly greater 
reductions (0.520 ± 0.319) in bacterial count than L. casei DN-114 001 within 
Actimel products (0.141 ± 0.081) after 3 hours of simulated gastric conditions.  
Lactobacilli strains within Original versions of each probiotic exhibited significantly 
greater reductions in number (0.485 ± 0.340) than strains contained within Light/Fat 
Free versions (0.176 ± 0.144).   L. casei Shirota within Yakult Original 
demonstrated the greatest reduction in number (0.787 ± 0.102) with L. casei DN-114 
001, within Actimel Fat Free, demonstrating the lowest reduction (0.099 ± 0.070), 
when compared with all probiotic versions.  
 
Table 1: Differences in mean reduction of bacterial count between probiotic brands and 
versions, during gastric, duodenal and total gastrointestinal transit 
 
 Least-Squares Mean Reduction of Bacterial Count* (log10 CFU 
ml-1) 
Gastric transit  
(0-3 hours) 






a 0.21290 0.99976a 
Yakult Light 0.25241
b 0.73347a 0.98589a 
Actimel Original 0.18383
b 0.04804b 0.23187b 
Actimel Fat Free 0.09859
b 0.32966 0.42825b 
Main Effect of BRAND    
Yakult 0.51964
a 0.47319a 0.99282a 
Actimel 0.14121
b 0.18885b 0.33006b 
Main Effect of 
VERSION 
   
Original 0.48535a 0.13047a 0.61581 
Light/Fat Free 0.17550b 0.53156b 0.70707 
 
Within each outlined group, values that do not share a lowercase letter are significantly 
different; P<0.05.*Of L. casei Shirota within Yakult versions and of L. casei DN-114 001 in 
Actimel versions. 
 
Effect of simulated duodenal transit on bacterial viability 
Parallel to gastric transit tolerance, during simulated duodenal transit (3-5 hours) 
reduction in bacterial count was significantly different between brands (F = 5.93; 
P<0.05) and versions of brands (F = 11.80; P<0.05) as shown in table 1.  Once 
again, reductions in bacterial count of L. casei Shirota within both versions of Yakult 
(0.473 ± 0.316) were significantly greater, on average, than reductions of L. casei 
DN-114 001 within both Actimel versions (0.189 ± 0.156).  In contrast to gastric 
transit tolerance, Lactobacilli strains within Light/Fat Free versions demonstrated 
significantly greater reductions (0.532 ± 0.258) than strains within Original versions 
(0.130 ± 0.098).  L. casei Shirota within Yakult Light demonstrated the greatest 
reduction in number (0.733 ± 0.207) with L. casei DN-114 001 in Actimel Original 
exhibiting the smallest reduction (0.048 ± 0.021). 
 
The mean reductions in bacterial count after simulated gastric and duodenal transit 
are shown in Figure 2, illustrating the elevated susceptibility of strains within Original 
versions to simulated gastric transit and of strains within Light/Fat Free versions to 




simulated duodenal conditions. A second General Linear Model, used to determine if 
reductions in bacterial count differed significantly between simulated gastric and 
duodenal transit, rendered the overall differences insignificant.   
 
 
Figure 2: Reductions in Bacterial Counts after Simulated Gastric and Duodenal Transit. 
Values are means from three replicates ± Standard Error of the Mean.  Blue bars (left) 




Ingestion of Yakult and Actimel products has become increasingly popular within 
current society, as a result of their vast range of proposed probiotic benefits and 
respective claims to “top up and support the work of beneficial bacteria in the gut” 
and “help strengthen natural defences” (Danone Actimel, 2009a; Yakult, 2006a).  
However, in order for these products to exert their proposed health-promoting 
effects, the Lactobacillus casei strains within must overcome the inhospitable 
conditions of the human gastrointestinal tract, and remain abundant, viable and 
active enough to subsequently colonise the intestinal epithelia.  This study assessed 
the capability of L. casei Shirota, within commercialised products Yakult Original 
and Yakult Light, and L. casei DN-114 001, within Actimel Original and Actimel 
Fat Free, to survive simulated in vitro gastric and duodenal transit.  The effect 
different food matrices had on the survival rates of bacteria was determined and 
furthermore, if strain tolerance to simulated gastric conditions differed significantly 
from strain tolerance to duodenal conditions.  This is the first known study to 
evaluate the tolerance of L. casei Shirota and L. casei DN-114 001 to in vitro gastric 
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Significantly greater (P<0.05) in vitro tolerance to simulated gastrointestinal transit 
(gastric plus duodenal digestion) was exhibited by L. casei DN-114 001 when 
compared with L. casei Shirota.  This is consistent with previous in vivo trials which 
demonstrated that L. casei DN-114 001 has the capacity to survive throughout the 
human intestinal tract (Oozeer et al, 2006; Tormo-Carnicer et al, 2006).  Although 
results of this study demonstrate that tolerance of L. casei Shirota to simulated 
gastrointestinal transit is poor and significantly lower (P<0.05) than that of L. casei 
DN-114 001, it also demonstrates the capability of this strain to survive and retain 
viability in these conditions.  Therefore, even though simulated gastrointestinal 
conditions results in a significant reduction of L. casei Shirota, it could potentially still 
reach its site of action alive to confer its proposed probiotic benefits.  This capability 
of L. casei Shirota to survive in vitro gastrointestinal transit is supported by earlier in 
vivo human feeding trials (Spanhaak et al, 1998; Tuohy et al, 2007). 
 
In order to reach the intestines, potentially probiotic bacteria must first survive 
passage through the stomach.  Over 2 litres of gastric juice, with a pH as low as 1.5, 
is secreted by parietal cells into the stomach each day (Morelli, 2000). Hydrochloric 
acid, the main constituent of gastric juice, helps destroy ingested microorganisms 
and stimulates the activation of pepsin, which degrades proteins into peptides.  In 
conjunction, these secretions provide a powerful barrier to the survival of ingested 
probiotic bacteria.  Species of the genus Lactobacillus have long been regarded as 
acid tolerant; however, gastric resistance has been shown to be highly strain-
dependent, with great variations between strains of the same species (Tannock, 
2004).  This is supported by the results of this study, with L. casei DN-114 001 
showing significantly (P<0.05) higher resistance to simulated gastric transit, than L. 
casei Shirota.  This higher resistance of L. casei DN-114 001 to gastric conditions 
may be attributable to elevated enzyme F0F1-ATPase activity which has been shown 
to be present in certain Lactobacillus strains (Corcoran et al, 2005).  This enzyme 
increases a bacterium’s tolerance to highly acidic conditions by generating a proton 
motive force across the cell wall, increasing the cell’s intracellular pH when 
extracellular pH is low (Fortier et al, 2003).  Poor tolerance of L. casei Shirota to 
gastric conditions is consistent with results obtained by Guo et al (2009) who 
demonstrated that the survival rate of L. casei Shirota significantly dropped after 4 
hours of exposure to simulated gastric juice at pH 2.5.  Contrarily, Curto et al (2011) 
reported that the concentration of secreted lactic acid (a good indicator of bacterial 
survival) and percentage recovery of L. casei DN-114 001, during simulated gastric 
digestion, was generally lower, compared with L. casei Shirota, indicating poorer 
adaptation of the bacterium to its environment.  A possible reason for these 
contradictory results is the differences in duration of simulated gastric digestion in 
each study, with Curto et al (2011) exposing strains to simulated gastric conditions 
for 1 hour, compared with a more realistic 3 hours in this study.  Thus, the true 
capability of each strain to adapt to gastric conditions was not adequately assessed.  
Findings of this study are also inconsistent with results obtained by Maragkoudakis 
et al (2006) whom reported complete loss of viability of both strains after 3 hours of 
exposure to pH 2 and pepsin.  However, this can be clearly attributed to the strains 
not being assessed within their commercialised food matrices, which have been 
shown to confer protection, to some extent, via the presence of milk substances.  
Milk and milk proteins, which are present in all Yakult and Actimel products, have 
been shown to improve gastrointestinal tolerance of Lactobacilli species; primarily 
decreasing their susceptibility to gastric transit and thus increasing their survival rate 
(Charteris et al, 1998; Curto et al, 2011).  




After passage through the stomach, probiotic bacteria must then survive duodenal 
transit, which is arguably less influential on bacterial viability than gastric transit 
(Holzapfel et al, 1998).  However, this has not been supported by findings of this 
study as no overall significant difference between bacterial reduction after gastric 
transit and bacterial reduction after duodenal transit was observed.  The capability of 
a bacterial probiotic to resist the action of bile is considered an imperative trait. Bile 
is secreted from the gall bladder into the duodenum where it acts in conjunction with 
digestive enzymes to emulsify and digest lipids.  Comparable to the degree of gastric 
tolerance demonstrated by each strain, L. casei Shirota exhibited a significantly 
greater (P<0.05) reduction in number, during simulated duodenal digestion, and 
therefore significantly lower tolerance to these conditions than L. casei DN-114 001.  
Differences in Bile Salt Hydrolase (BSH) activity (an enzyme which deconjugates 
and decreases the digestive capability of bile) may explain the variation in resistance 
to duodenal conditions between strains.  However, Maragkoudakis et al (2006) 
reported partial bile salt hydrolysis by L. casei Shirota and no bile salt hydrolysis by 
L. casei DN-114 001; contradictory of results obtained in this study. Results acquired 
by Curto et al (2011) are one of few which can be effectively compared to results of 
this study, as tolerance to duodenal digestion is assessed immediately following 
simulated gastric digestion, with no removal or replacement of strains between 
stages.  Supportive of findings in this study, L. casei DN-114 001 in milk, showed 
higher percentage recovery after gastric plus 1 and 2 hours of duodenal digestion 
than L. casei Shirota; although the differences were rendered insignificant.   
 
Observed differences in strain tolerance, to simulated gastric and duodenal transit, 
may not be simply attributable to their capability to adapt, but may be correlated with 
differences in food matrix composition. As discussed previously, food matrix 
composition, particularly the presence of milk substances, increases the capacity of 
strains to survive the gastrointestinal tract.  However, further correlations between 
the nutritional content of each commercialised food matrix and bacterial survival 
have also been observed.  Results of the Two-Sample T-tests revealed that the 
reduction in number of L. casei DN-114 001, within Actimel Original, after 5 hours of 
simulated gastrointestinal transit, was not significant compared to its control, 
whereas the reduction of the same strain, within Actimel Fat Free, after 5 hours was 
significant (P<0.05). The composition of Actimel Original, which contains higher 
levels of fat and carbohydrate, must therefore confer a greater degree of protection 
to L. casei DN-114 001 than Actimel Fat Free (Danone Actimel, 2009b).   
 
The significant differences (P<0.05) observed between gastrointestinal tolerance of 
L. casei Shirota, within Yakult products, compared to L. casei DN-114 001, within 
Actimel products, may also be potentially attributable to the differences in food 
matrix composition.  For example, Actimel versions contain over twice as much 
protein as Yakult versions; providing a greater proportion of non-bacterial proteins 
for hydrochloric acid and pepsin to act on during gastric transit (Danone Actimel, 
2009b; Yakult, 2006b).  Furthermore, Actimel products additionally contain yoghurt 
cultures, which also confer some protection against simulated gastric conditions.  In 
conjunction, these components of Actimel food matrices decrease the susceptibility 
of L. casei DN-114 001 to simulated gastric transit and hence, increase its chance at 
surviving subsequent simulated duodenal transit.   
 
When comparing food matrix composition of Original and Light/Fat Free versions of 
each brand, no significant correlations with overall bacterial count reductions were 




observed.  However, when simulated gastric and duodenal conditions were regarded 
separately, whether the matrix was of an Original or Light/Fat Free variety 
significantly affected bacterial survival.  Strains within Original versions of Yakult 
and Actimel exhibited significantly (P< 0.05) greater reduction in numbers and thus 
significantly lower tolerance to simulated gastric conditions than strains within 
Light/Fat Free versions.  Therefore, the composition of Light/Fat Free versions, of 
Yakult and Actimel, confer a greater protective effect to strains contained within 
each product, than the composition of Original versions, when exposed to simulated 
gastric conditions.    In contrast to gastric tolerance, strains within Light/Fat Free 
versions of each brand experienced significantly greater (P<0.05) reductions in 
number and thus, significantly lower tolerance to duodenal conditions, than strains 
contained within Original versions.  This is likely to be attributable to the higher fat 
content of Original versions compared to Light/Fat Free versions; providing more 
non-bacterial lipids for bile to act on (Danone Actimel, 2009b; Yakult, 2006b).   
 
The major strength of this study is that it takes into account the food matrices each 
bacterium is sold, and claims to confer benefits, within.  In previous studies, the 
bacterium is typically isolated before its survivability during simulated gastrointestinal 
transit is assessed.  A further important strength of this study is the follow-on of 
simulated duodenal transit immediately after simulated gastric transit; imitating in 
vivo human gastrointestinal digestion to a greater degree.  By assessing a strain’s 
tolerance to gastric and duodenal conditions separately, the majority of previous 
studies have led to misleading predictions of a strain’s probiotic potential.  
Furthermore, the duration of exposure to simulated gastric and duodenal conditions, 
of respectively 3 and 2 hours, are more realistic of in vivo human digestion compared 
with the duration’s used in earlier studies.  Hence, a more accurate prediction of a 
strain’s ability to survive in vivo gastrointestinal transit is achieved.  The inclusion of 
pepsin in this study also improves the degree of similarity between in vitro and in 
vivo human gastric conditions.    
 
However, a number of limitations of the methodology used in this study contribute to 
notable dissimilarities to in vivo human gastrointestinal conditions.  For instance, the 
bile and pepsin used are of bovine and porcine origin respectively, which may have 
greater or lower digestive capability compared to those of human origin.  
Furthermore, the pH of the stomach varies greatly throughout digestion and can 
reach as low as 1.5.  Thus, to effectively determine the survivability of each strain 
during gastric transit, the strains should have been exposed to a broader pH range.  
The secretion of pancreatin, which consists of digestive enzymes trypsin, amylase 
and lipase, into the duodenum is also overlooked during this study; notably 
increasing the chance of each strain’s survival during simulated duodenal digestion.  
Even though the survivability of each strain was assessed, their aptitude to adhere to 
intestinal cells was not.  Thus, although all strains retained viability after 5 hours of 
simulated gastrointestinal transit, with L. casei DN-114 001 (within Actimel Original) 
demonstrating resistance to gastrointestinal conditions, they may be incapable of 
colonising the intestinal tract and hence, incapable of bestowing their suggested 
therapeutic benefits.   
 
In conclusion, strains contained within commercialised Yakult and Actimel 
products of Original and Light/Fat Free varieties retained viability after 5 hours of 
exposure to simulated gastrointestinal transit.  Whether the product was of an 
Original or a Light/Fat Free variety did not have an overall significant effect on the 




survival of each strain, but did when gastric and duodenal tolerance was examined 
separately; possibly due to the variation in nutritional content and focus of 
gastrointestinal secretions.  The survival of L. casei Shirota within both Yakult 
Original and Yakult Light was significantly affected during simulated gastrointestinal 
transit, compared with the survival of L. casei DN-114 001 within Actimel Original 
and Actimel Fat Free, suggesting L. casei Shirota has poorer tolerance to 
gastrointestinal conditions. However, when compared to control results, the survival 
of L. casei DN-114 001 within Actimel Fat Free was significantly affected by 
gastrointestinal conditions, whereas survival of the same strain within Actimel 
Original was not significantly affected; a strong implication that food matrix 
composition is significantly correlated with bacterial survival.  Out of the four probiotic 
products assessed; L. casei DN-114 001, contained within Actimel Original, 
demonstrated resistance to simulated gastrointestinal conditions.  However, this 
does not denote probiotic functionality as notable dissimilarities between in vivo 
gastrointestinal tract conditions and the in vitro conditions employed in this study 
remain. Furthermore, despite the fact that all strains retained viability, their capacity 
to adhere to intestinal epithelia and bestow their proposed therapeutic benefits has 
not been confirmed. 
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